Johnson & Johnson (JNJ) Q2 2025: Oncology Jumps 22% as Portfolio Depth Offsets Stellara LOE
Johnson & Johnson’s second quarter showcased the power of portfolio breadth as oncology’s 22% growth and MedTech’s cardiovascular surge neutralized a $1.2B Stellara loss of exclusivity headwind. The company raised both sales and EPS guidance, signaling confidence in pipeline catalysts and continued acceleration in the back half of 2025. Investors should watch for transformative product launches and margin dynamics as J&J leans into high-growth categories and navigates U.S. policy shifts.
Summary
- Oncology and MedTech Outperformance: Double-digit growth in key franchises fueled robust top-line results despite legacy erosion.
- Pipeline and Launch Momentum: Major late-stage assets and near-term launches position J&J for sustained leadership across high-value categories.
- Margin and Policy Watch: Operating leverage and tariff impacts remain key as J&J reinvests for innovation while navigating global cost headwinds.
Performance Analysis
Johnson & Johnson delivered $23.7 billion in Q2 sales, up 4.6% operationally, with U.S. growth of 7.8% and international growth muted by biosimilar competition and COVID-19 vaccine roll-off. Innovative Medicine, now 64% of total sales, grew 3.8% operationally to $15.2 billion, overcoming a 1,170 basis point drag from Stellara, a blockbuster immunology drug facing biosimilar erosion. MedTech, accounting for 36% of revenue, accelerated to 6.1% operational growth, led by cardiovascular (22%+), surgical vision, and wound closure, while orthopedics remained a drag at minus 1.6%.
Adjusted EPS declined 1.8% YoY, reflecting higher interest expense from the $14.5 billion intracellular acquisition and gross profit erosion tied to Stellara. Margins compressed in both segments: Innovative Medicine fell to 42.7% from 44.6%, and MedTech to 22.2% from 25.7%, pressured by product mix, acquisition amortization, and macro factors, including China’s volume-based procurement (VBP) regime. Notably, J&J raised full-year sales guidance by $2 billion and EPS by $0.25, reflecting confidence in accelerating second-half performance, pipeline launches, and foreign exchange tailwinds.
- Oncology Drives Top-Line: Q2 oncology sales jumped 22.3%, with Darzalex, Carvicti, and new launches like Ribrovent plus Lasclus outperforming and building toward a $50B 2030 target.
- Stellara Erosion Managed: Stellara’s 43% decline was offset by 13 double-digit growth brands, especially in immunology and neuroscience.
- MedTech Cardiovascular Momentum: Cardiovascular grew 22%+, with Abiomed and Shockwave acquisitions exceeding deal models and electrophysiology (EP) rebounding with new products and global expansion.
J&J’s diversified model and innovation cadence allowed it to grow through a multibillion-dollar LOE event, a rare feat in large-cap pharma and medtech. The company’s ability to reinvest, execute on launches, and maintain financial discipline underpins its elevated guidance and forward momentum.
Executive Commentary
"No other healthcare company has grown through the loss of exclusivity of a multi-billion dollar product in the first year. In our case, Stellara. And yet, that is exactly what we are doing, and for the second quarter in a row."
Joaquin Duato, Chairman and Chief Executive Officer
"The progress across our pipeline in the first half of the year heightens our conviction to achieve, and I'd be willing to bet likely beat, the upper end of the growth targets we conveyed at our 2023 Enterprise Business Review."
Joe Wolk, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Oncology as a Core Growth Engine
Oncology delivered 22.3% operational growth, driven by broad-based momentum across multiple myeloma, lung, and bladder cancer. Darzalex, Carvicti, and the launch of Ribrovent plus Lasclus are expanding J&J’s share, with management reiterating a bold $50B sales target by 2030. TAR200, a novel bladder cancer therapy, is expected to launch later this year with $5B peak sales potential, and pipeline assets like tri-specific antibodies and TAR210 offer additional upside.
2. Immunology and Neuroscience Resilience
Despite Stellara’s LOE, immunology brands like Trenfaya (up 30%) and neuroscience assets Spravato (up 53%) and Caplita are driving robust growth, supported by new indications and pipeline progress. Oral peptide icotroquinra is on track for FDA filing, targeting the IL-23 pathway in psoriasis and IBD, and could set a new standard in oral immunology therapy.
3. MedTech Portfolio Shifts to High-Growth Segments
Cardiovascular led MedTech’s resurgence, with Abiomed and Shockwave outperforming, and electrophysiology (EP) regaining share through new products like VeriPulse. Vision also posted near double-digit growth in surgical products, while orthopedics lagged but is expected to improve with new launches and regulatory approvals. The upcoming Otava robotic surgery system and digital ecosystem (Polyphonic) are positioned to capture share in surgical robotics.
4. Capital Allocation and Margin Management
J&J continues to invest heavily in R&D (15% of sales) and pipeline acquisitions, while navigating margin headwinds from product mix, amortization, and tariffs. Efficiency programs are expected to restore operating margin improvement by year-end, with full-year guidance reaffirmed despite near-term dilution from the intracellular deal and higher global tax rates ahead in 2026.
5. U.S. Policy and Supply Chain Adaptation
J&J is proactively investing $55B in U.S. manufacturing, aiming to localize production in response to evolving tariff and tax policy. Management signaled agility in its supply chain, with sufficient flexibility to adapt to potential 2026 changes and a focus on leveraging favorable R&D expensing and depreciation rules under the new tax regime.
Key Considerations
J&J’s Q2 results highlight the strategic value of a diversified, innovation-led platform that can absorb major patent cliffs while funding pipeline acceleration and margin restoration. The following factors are critical for investors:
- Oncology Outperformance: Oncology’s 22% growth and pipeline depth reinforce J&J’s ambition to become the top global oncology company, with multiple assets targeting $5B+ peak sales.
- MedTech Cardiovascular and Vision Strength: Cardiovascular and vision are offsetting softness in orthopedics and surgery, with new launches and acquisitions driving above-market growth.
- Margin Compression and Recovery Path: Gross and operating margins remain pressured by mix and acquisition amortization, but efficiency initiatives and pipeline leverage are expected to drive improvement in H2.
- Tariff and Tax Policy Implications: U.S. policy changes create both cost risks and investment incentives, with J&J’s supply chain flexibility and $55B U.S. investment plan mitigating longer-term uncertainty.
- Pipeline Execution and Launch Cadence: Multiple near-term launches (TAR200, icotroquinra, Otava, new vision products) and late-stage pipeline readouts will determine the sustainability of above-market growth.
Risks
Key risks include further erosion from Stellara biosimilars, continued margin pressure from product mix and global procurement regimes, and execution risk around major pipeline launches and integration of recent acquisitions. U.S. tariff and tax policy changes could disrupt supply chains or increase costs, while litigation (notably talc) remains a background overhang. Management’s guidance assumes steady macro and policy conditions, but volatility in FX, global pricing, and regulatory timelines could create additional headwinds.
Forward Outlook
For Q3 2025, J&J guided to:
- Operational sales growth acceleration in both Innovative Medicine and MedTech,
- Higher second-half margin improvement driven by efficiency programs and normalization of one-time charges.
For full-year 2025, management raised guidance:
- Operational sales growth of 4.5% to 5% (midpoint $92.9B),
- Reported sales growth of 5.1% to 5.6% (midpoint $93.4B),
- Adjusted EPS of $10.80 to $10.90, up $0.25 from prior guidance.
Management expects pipeline launches and accelerating momentum in high-growth franchises to drive above-peer growth in the back half of 2025, with continued focus on margin restoration and U.S. supply chain adaptation.
- Stellara erosion expected to intensify, offset by new launches and brand expansion.
- Tariff impact for 2025 now $200M, with flexibility to reinvest in innovation.
Takeaways
J&J’s ability to outgrow a multibillion-dollar LOE event, raise guidance, and accelerate high-value launches underscores the resilience and optionality of its business model.
- Portfolio Depth Is a Strategic Moat: Diversification across innovative medicine and medtech enables J&J to absorb shocks and fund growth, with oncology and cardiovascular now the primary engines.
- Pipeline Execution Is Pivotal: Near-term launches (TAR200, icotroquinra, Otava) and successful integration of acquired assets will determine whether J&J can sustain above-market growth and margin expansion.
- Margin and Policy Remain Key Watchpoints: Investors should monitor the pace of margin recovery, the impact of U.S. policy shifts, and the company’s ability to reinvest for innovation while protecting bottom-line growth.
Conclusion
Johnson & Johnson’s Q2 2025 results validate its strategy of leveraging portfolio depth and innovation to sustain growth despite legacy headwinds. With oncology and MedTech leading the charge, and a robust pipeline set to deliver multiple catalysts, J&J is positioned for continued outperformance—provided it executes on launches and manages evolving cost and policy risks.
Industry Read-Through
J&J’s ability to offset a major LOE with pipeline-fueled growth and MedTech acceleration sets a new benchmark for diversified healthcare peers. The company’s proactive U.S. manufacturing investment and agile supply chain strategy highlight the growing importance of local production in response to policy risk. Oncology’s continued outperformance and the shift to high-growth MedTech segments (cardiovascular, vision, surgical robotics) signal where capital and R&D are flowing across the sector. Margin compression from product mix and acquisition amortization is a caution for others pursuing aggressive pipeline M&A or facing similar patent cliffs. Watch for competitors to emulate J&J’s approach to innovation, U.S. localization, and portfolio balance as industry dynamics evolve.